Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 10,865 matching trials from the live ClinicalTrials.gov search.

Filters: Nashville, Tennessee Clear all

Conditions: HIV Infections
Interventions: Atazanavir, Didanosine (enteric-coated), Efavirenz, Emtricitabine, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine/Zidovudine; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 1,571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 27
States / cities: Los Angeles, California • Torrance, California • Denver, Colorado + 16 more

Conditions: Prostate Cancer
Interventions: Abiraterone acetate, Placebo, Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,088 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 48
States / cities: Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 45 more

Conditions: Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell
Interventions: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 16
States / cities: Jonesboro, Arkansas • Gainesville, Florida • Naples, Florida + 12 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: Fingolimod, Standard MS DMTs; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 142
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more

Conditions: Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Nivolumab, Pazopanib, Sunitinib, Ipilimumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 10
States / cities: Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 7 more

Conditions: Essential Tremor
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 26
States / cities: Anniston, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 23 more

Conditions: HDL, Health, Subjective
Interventions: Dietary supplementation; Dietary Supplement
Lead sponsor: Metagenics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Behavior and Behavior Mechanisms
Interventions: Demand Informed Moderator Analysis; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Gallatin, Tennessee • Lebanon, Tennessee • Murfreesboro, Tennessee + 2 more

Conditions: Neoplasms, Prostate
Interventions: Dutasteride, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 8,231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 297
States / cities: Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 236 more

Conditions: Advanced or Metastatic Solid Tumors
Interventions: ERAS-007, ERAS-601; Drug
Lead sponsor: Erasca, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 2 more

Conditions: Actinic Keratosis
Interventions: Imiquimod cream, Placebo cream; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 22 more

Conditions: Menorrhagia
Interventions: Cerene(R) Cryotherapy Device; Device
Lead sponsor: Channel Medsystems; Industry
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 9
States / cities: Arlington Heights, Illinois • Naperville, Illinois • Fort Wayne, Indiana + 6 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Selexipag, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 43
States / cities: Mobile, Alabama • Tucson, Arizona • La Jolla, California + 32 more

Conditions: Asthma
Interventions: Levalbuterol tartrate MDI, racemic albuterol MDI, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 45
States / cities: Montgomery, Alabama • Jonesboro, Arkansas • Corona, California + 39 more

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 48
States / cities: Irvine, California • Loma Linda, California • Palm Springs, California + 39 more

Conditions: Hypertension, Pure Autonomic Failure
Interventions: L-NMMA, Trimethaphan; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Ischemic Stroke
Interventions: Endovascular Mechanical Thrombectomy; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Englewood, Colorado + 17 more

Conditions: Colorectal Neoplasms
Interventions: Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 989
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more

Conditions: Ovarian Cancer
Interventions: Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 110
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more

Conditions: Sarcoma
Interventions: dactinomycin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy, filgrastim; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 49 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 143
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 118 more

Conditions: Hyperphosphatemia
Interventions: Tenapanor, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 32
States / cities: Huntsville, Alabama • Riverside, California • Denver, Colorado + 28 more

Conditions: Juvenile Huntington Disease, Juvenile-Onset Huntington Disease
Interventions: Not listed
Lead sponsor: University of Iowa; Other
Eligibility: 4 Years to 30 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Sacramento, California • Iowa City, Iowa • Philadelphia, Pennsylvania + 2 more

Conditions: Tuberculosis
Interventions: Rifapentine, 25-desacetyl Rifapentine, Isoniazid; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 20
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more

Conditions: Eosinophilic Asthma
Interventions: Reslizumab; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 48
States / cities: Scottsdale, Arizona • Anaheim, California • Fountain Valley, California + 39 more

Search by objective public record fields.

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

A Study to Evaluate SAGE-217 in Participants With Essential Tremor

HDL Function Dietary Supplement Safety and QOL

Translational Research to Inform Interventions for Challenging Behavior

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)

A CLinical Study to Evaluate the Safety And Effectiveness of the CeRene DevIce to Treat HeavY Menstrual Bleeding

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

Evaluation of Vitrectomy for Diabetic Macular Edema

Nitric Oxide and the Autonomic Nervous System

POSITIVE Stroke Clinical Trial

S0820, Adenoma and Second Primary Prevention Trial

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma